RxDoctor Payments Data

Thong Tram, DO

Internal Medicine · Folsom, CANPI 1376575985

Payments from drug & device makers

$10,722in general payments, 2019–2025

Across 580 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$899
  • Novo Nordisk$795
  • Pfizer$779
  • Boehringer Ingelheim$617
  • Bayer$590
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$10,60199%
  • Education$611%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca79$1,541
AbbVie(2 entities)54$899
Novo Nordisk60$795
Pfizer45$779
Boehringer Ingelheim30$617
Bayer24$590
GSK25$522
Merck27$469
Antares Pharma, Inc.30$400
Johnson & Johnson14$287
Mannkind Corporation14$277
Lilly USA, LLC13$272
Amgen(2 entities)15$251
Amarin Pharma, Inc.16$221
Biohaven Pharmaceuticals, Inc.7$196
Sanofi-aventis U.S. LLC11$195
Exact Sciences8$175
Dexcom, Inc.6$150
Kowa Pharmaceuticals America, Inc.6$127
Philips North America LLC4$119
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$113
Radius Health, Inc.4$111
E.r. Squibb & Sons, L.L.C.5$99
Almatica Pharma LLC6$95
Intra-sana Laboratories3$79
Novartis4$78
Abbott4$75
Mylan Specialty L.p.3$72
Vanda Pharmaceuticals Inc.3$69
Halozyme Inc3$67
Idorsia Pharmaceuticals US Inc4$59
Vertex2$53
Medtronic2$53
Sunovion Pharmaceuticals Inc.5$45
Ironwood Pharmaceuticals, Inc2$45
Bausch Health US, LLC3$44
Takeda Pharmaceuticals U.S.A., Inc.2$44
United Therapeutics Corporation2$42
Electromed, Inc.2$39
Sumitomo Pharma America, Inc.2$39
Boston Scientific2$39
Verity Pharmaceuticals Inc.2$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Smith+Nephew1$27
RGH Enterprises LLC1$27
Agios Pharmaceuticals, Inc.1$26
Biogen1$25
Qiagen, LLC1$24
Corcept Therapeutics1$22
Biohaven Pharmaceutical Holding Company Ltd.1$22
Astellas Pharma US Inc1$22
Aimmune Therapeutics, Inc.1$21
Azurity Pharmaceuticals, Inc.1$21
Actelion Pharmaceuticals US, Inc.1$21
Bardy Diagnostics, Inc.1$18
VBI Vaccine (delaware) Inc.1$18
Scpharmaceuticals Inc.1$18
Alfasigma USA, Inc.1$17
Currax Pharmaceuticals LLC1$17
Xeris Pharmaceuticals, Inc.1$17

How this compares

$10,722 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$146,575
Medicare patients
351
Services billed
9,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$105,747
JardianceEmpagliflozin62$72,876
OzempicSemaglutide66$70,300
RybelsusSemaglutide24$51,677
ProliaDenosumab24$40,782
XifaxanRifaximin11$36,128
XareltoRivaroxaban23$33,465
FarxigaDapagliflozin Propanediol29$30,520
LinzessLinaclotide18$30,335
PancreazeLipase/Protease/Amylase12$28,436
MultaqDronedarone Hcl14$21,757
JanuviaSitagliptin Phosphate14$21,611
EntrestoSacubitril/Valsartan14$20,537
MounjaroTirzepatide11$17,188
Soliqua 100-33Insulin Glargine/Lixisenatide14$14,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$795$121,97790 claims
PfizerEliquis$779$105,747117 claims
Boehringer IngelheimJardiance, Trijardy Xr$617$79,32373 claims
AmgenProlia$251$40,78224 claims
Sanofi-aventis U.S. LLCMultaq, Soliqua 100-33$195$36,49628 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$113$36,12811 claims
AstraZenecaFarxiga, Symbicort$1,541$34,82943 claims
AbbVieLinzess, Synthroid$899$34,19872 claims
Johnson & JohnsonXarelto$287$33,46523 claims
MerckJanuvia, Belsomra$469$29,45532 claims
NovartisEntresto$78$20,53714 claims
Lilly USA, LLCMounjaro$272$17,18811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Folsom

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →